BioAtla, Inc. (BCAB) Form S-1 — Oct 19, 2026
BioAtla filed an S-1 registering the resale by Yorkville of up to 8,182,110 shares under a $40M Standby Equity Purchase Agreement signed October 15, 2026. If all registered shares were issued, they would equal roughly 490.5% of the 1,668,261 shares currently outstanding, with Yorkville buying at 97% of the lowest daily VWAP during each pricing period. The filing discloses substantial doubt about BioAtla's ability to continue as a going concern: the company had only about $1.5 million in cash at June 30, 2026, against a $551.5 million accumulated deficit, and recently cut roughly 70% of its workforce.
Key figures
- Net Income
- net loss of $59.6M (FY2025), $69.8M (FY2024); $5.9M loss for six months ended June 30, 2026 vs $34.0M prior year
- Cash Position
- 1500000
- Gross Proceeds
- 40000000
- Offering Price
- 97% of lowest daily VWAP during 3-day pricing period
- Shares Offered
- 8182110
- Shares Outstanding
- 1668261
- Commitment fee
- $500,000
- Last sale price
- $1.36 (October 16, 2026)
- Sepa term months
- 36
- Commitment shares
- 182110
- Accumulated deficit
- $551.5 million as of June 30, 2026
- Placement agent fee
- 3% of aggregate purchase price of Advance Shares
- Workforce reduction
- approximately 70%
- Ownership limitation
- 4.99%
- Potential dilution percent
- 490.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.